Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Overland ADCT Says Zynolonta BLA Accepted for China Review as Lymphoma Therapy

publication date: Jul 24, 2023

Overland ADCT BioPharma reported that China’s NMPA has accepted for review a Biologics License Application for Zynolonta® to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) as a third-line therapy. Overland ADCT is a JV established by Overland Pharmaceuticals, a Boston-Shanghai company, with Lausanne’s ADC Therapeutics. Overland brings western drugs to Asia, while ADC discovered Zynolonta. In 2020, the two companies formed a $50 million JV for Asia rights to four of ADC’s drugs. Zynolonta®, which has been approved for DLBCL in the US and EU, is the most advanced of the four. More details....

Stock Symbol: (NYSE: ADCT)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital